Company Description
Hemab Therapeutics is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience.
Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases.
Our lead asset, sutacimig (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency.
Our second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease.
We are also advancing multiple preclinical and discovery-stage assets.
| Country | United States |
| Founded | 2020 |
| IPO Date | May 1, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 72 |
| CEO | Benny Sørensen, M.D., Ph.D. |
Contact Details
Address: 101 Main Street, Suite 1220 Cambridge, MA 02142 United States | |
| Phone | (617) 553-3952 |
| Website | hemab.com |
Stock Details
| Ticker Symbol | COAG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002114044 |
| Employer ID | 41-4241952 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Benny Sørensen, M.D., Ph.D | President and Chief Executive Officer, Director |
| Mads Behrndt, M.Sc | Chief Financial Officer and General Manager |
| Catherine Madigan, M.D | Chief Medical Officer |
| Ananthram Murthy, Ph.D., M.Sc. | Chief Operating Officer |
| John Maraganore, Ph.D. | Chair of the Board of Directors |
| Linda Bain | Director |
| Laura Tadvalkar, Ph.D. | Director |
| Akshay Vaishnaw, M.D., Ph.D | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Apr 27, 2026 | 8-A12B | Registration of securities |
| Apr 27, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Apr 10, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Apr 2, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Feb 27, 2026 | DRS | [Cover] Draft Registration Statement |